Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer.
Identifieur interne : 001071 ( Main/Exploration ); précédent : 001070; suivant : 001072Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer.
Auteurs : H. Nakamura [Japon] ; J. Bai ; Y. Nishinaka ; S. Ueda ; T. Sasada ; G. Ohshio ; M. Imamura ; A. Takabayashi ; Y. Yamaoka ; J. YodoiSource :
- Cancer detection and prevention [ 0361-090X ] ; 2000.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Antinéoplasiques (pharmacologie), Biosynthèse des protéines (MeSH), Carcinome canalaire du sein (anatomopathologie), Carcinome canalaire du sein (métabolisme), Cellules cancéreuses en culture (effets des médicaments et des substances chimiques), Cellules cancéreuses en culture (métabolisme), Cisplatine (pharmacologie), Cystadénocarcinome (anatomopathologie), Cystadénocarcinome (métabolisme), Glutarédoxines (MeSH), Humains (MeSH), Immunotransfert (MeSH), Marqueurs biologiques tumoraux (biosynthèse), Marqueurs biologiques tumoraux (sang), Oxidoreductases (MeSH), Oxydoréduction (MeSH), Pronostic (MeSH), Résistance aux médicaments antinéoplasiques (MeSH), Sujet âgé (MeSH), Test ELISA (MeSH), Thiorédoxines (biosynthèse), Thiorédoxines (sang), Tumeurs du pancréas (anatomopathologie), Tumeurs du pancréas (métabolisme).
- MESH :
- anatomopathologie : Carcinome canalaire du sein, Cystadénocarcinome, Tumeurs du pancréas.
- biosynthèse : Marqueurs biologiques tumoraux, Thiorédoxines.
- effets des médicaments et des substances chimiques : Cellules cancéreuses en culture.
- métabolisme : Carcinome canalaire du sein, Cellules cancéreuses en culture, Cystadénocarcinome, Tumeurs du pancréas.
- pharmacologie : Antinéoplasiques, Cisplatine.
- sang : Marqueurs biologiques tumoraux, Thiorédoxines.
- Adulte, Adulte d'âge moyen, Biosynthèse des protéines, Glutarédoxines, Humains, Immunotransfert, Oxidoreductases, Oxydoréduction, Pronostic, Résistance aux médicaments antinéoplasiques, Sujet âgé, Test ELISA.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Antineoplastic Agents (pharmacology), Biomarkers, Tumor (biosynthesis), Biomarkers, Tumor (blood), Carcinoma, Ductal, Breast (metabolism), Carcinoma, Ductal, Breast (pathology), Cisplatin (pharmacology), Cystadenocarcinoma (metabolism), Cystadenocarcinoma (pathology), Drug Resistance, Neoplasm (MeSH), Enzyme-Linked Immunosorbent Assay (MeSH), Glutaredoxins (MeSH), Humans (MeSH), Immunoblotting (MeSH), Middle Aged (MeSH), Oxidation-Reduction (MeSH), Oxidoreductases (MeSH), Pancreatic Neoplasms (metabolism), Pancreatic Neoplasms (pathology), Prognosis (MeSH), Protein Biosynthesis (MeSH), Thioredoxins (biosynthesis), Thioredoxins (blood), Tumor Cells, Cultured (drug effects), Tumor Cells, Cultured (metabolism).
- MESH :
- chemical , biosynthesis : Biomarkers, Tumor, Thioredoxins.
- chemical , blood : Biomarkers, Tumor, Thioredoxins.
- chemical , pharmacology : Antineoplastic Agents, Cisplatin.
- drug effects : Tumor Cells, Cultured.
- metabolism : Carcinoma, Ductal, Breast, Cystadenocarcinoma, Pancreatic Neoplasms, Tumor Cells, Cultured.
- pathology : Carcinoma, Ductal, Breast, Cystadenocarcinoma, Pancreatic Neoplasms.
- Adult, Aged, Drug Resistance, Neoplasm, Enzyme-Linked Immunosorbent Assay, Glutaredoxins, Humans, Immunoblotting, Middle Aged, Oxidation-Reduction, Oxidoreductases, Prognosis, Protein Biosynthesis.
Abstract
Pancreatic cancer (pancreatic ductal carcinoma) is one of the most malignant solid tumors with poor prognosis. There is accumulating evidence that cellular reduction/oxidation (redox) status is deeply involved in the growth promotion and drug resistance of cancer cells. We therefore investigated the expression of redox-regulating proteins, such as thioredoxin (TRX) and glutaredoxin (GRX) in surgically resected pancreatic tissues and cis-diamminedichloroplatinum (CDDP)-resistant cells. Plasma levels of TRX were also measured in subjects with pancreatic diseases. Pancreatic ductal carcinoma tissues were immunohistochemically more positive for TRX (24/32 cases) and GRX (29/32 cases) than pancreatic cystadenocarcinoma or normal pancreas tissues. Plasma levels of TRX (mean +/- SD) measured by ELISA were significantly higher in patients with pancreatic ductal carcinoma (54.8 +/- 37.6 ng/ml, n = 60) than in healthy controls (24.4 +/- 12.9 ng/ml, n = 81). CDDP-resistant subclones of HeLa cells, HeLa-CP5 cells, had higher expression of TRX (1.5 fold) and GRX (1.6 fold) compared with parental HeLa cells by immunoblotting. These results indicate the possible association of TRX and GRX with malignant potential of pancreatic ductal carcinoma.
PubMed: 10757123
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer.</title><author><name sortKey="Nakamura, H" sort="Nakamura, H" uniqKey="Nakamura H" first="H" last="Nakamura">H. Nakamura</name><affiliation wicri:level="4"><nlm:affiliation>Department of Biological Responses, Institute for Virus Research, Kyoto University, Sakyo, Japan. hnakamur@virus.kyoto-u.ac.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Biological Responses, Institute for Virus Research, Kyoto University, Sakyo</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author><author><name sortKey="Bai, J" sort="Bai, J" uniqKey="Bai J" first="J" last="Bai">J. Bai</name></author><author><name sortKey="Nishinaka, Y" sort="Nishinaka, Y" uniqKey="Nishinaka Y" first="Y" last="Nishinaka">Y. Nishinaka</name></author><author><name sortKey="Ueda, S" sort="Ueda, S" uniqKey="Ueda S" first="S" last="Ueda">S. Ueda</name></author><author><name sortKey="Sasada, T" sort="Sasada, T" uniqKey="Sasada T" first="T" last="Sasada">T. Sasada</name></author><author><name sortKey="Ohshio, G" sort="Ohshio, G" uniqKey="Ohshio G" first="G" last="Ohshio">G. Ohshio</name></author><author><name sortKey="Imamura, M" sort="Imamura, M" uniqKey="Imamura M" first="M" last="Imamura">M. Imamura</name></author><author><name sortKey="Takabayashi, A" sort="Takabayashi, A" uniqKey="Takabayashi A" first="A" last="Takabayashi">A. Takabayashi</name></author><author><name sortKey="Yamaoka, Y" sort="Yamaoka, Y" uniqKey="Yamaoka Y" first="Y" last="Yamaoka">Y. Yamaoka</name></author><author><name sortKey="Yodoi, J" sort="Yodoi, J" uniqKey="Yodoi J" first="J" last="Yodoi">J. Yodoi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:10757123</idno><idno type="pmid">10757123</idno><idno type="wicri:Area/Main/Corpus">001082</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001082</idno><idno type="wicri:Area/Main/Curation">001082</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001082</idno><idno type="wicri:Area/Main/Exploration">001082</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer.</title><author><name sortKey="Nakamura, H" sort="Nakamura, H" uniqKey="Nakamura H" first="H" last="Nakamura">H. Nakamura</name><affiliation wicri:level="4"><nlm:affiliation>Department of Biological Responses, Institute for Virus Research, Kyoto University, Sakyo, Japan. hnakamur@virus.kyoto-u.ac.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Biological Responses, Institute for Virus Research, Kyoto University, Sakyo</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author><author><name sortKey="Bai, J" sort="Bai, J" uniqKey="Bai J" first="J" last="Bai">J. Bai</name></author><author><name sortKey="Nishinaka, Y" sort="Nishinaka, Y" uniqKey="Nishinaka Y" first="Y" last="Nishinaka">Y. Nishinaka</name></author><author><name sortKey="Ueda, S" sort="Ueda, S" uniqKey="Ueda S" first="S" last="Ueda">S. Ueda</name></author><author><name sortKey="Sasada, T" sort="Sasada, T" uniqKey="Sasada T" first="T" last="Sasada">T. Sasada</name></author><author><name sortKey="Ohshio, G" sort="Ohshio, G" uniqKey="Ohshio G" first="G" last="Ohshio">G. Ohshio</name></author><author><name sortKey="Imamura, M" sort="Imamura, M" uniqKey="Imamura M" first="M" last="Imamura">M. Imamura</name></author><author><name sortKey="Takabayashi, A" sort="Takabayashi, A" uniqKey="Takabayashi A" first="A" last="Takabayashi">A. Takabayashi</name></author><author><name sortKey="Yamaoka, Y" sort="Yamaoka, Y" uniqKey="Yamaoka Y" first="Y" last="Yamaoka">Y. Yamaoka</name></author><author><name sortKey="Yodoi, J" sort="Yodoi, J" uniqKey="Yodoi J" first="J" last="Yodoi">J. Yodoi</name></author></analytic><series><title level="j">Cancer detection and prevention</title><idno type="ISSN">0361-090X</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Antineoplastic Agents (pharmacology)</term><term>Biomarkers, Tumor (biosynthesis)</term><term>Biomarkers, Tumor (blood)</term><term>Carcinoma, Ductal, Breast (metabolism)</term><term>Carcinoma, Ductal, Breast (pathology)</term><term>Cisplatin (pharmacology)</term><term>Cystadenocarcinoma (metabolism)</term><term>Cystadenocarcinoma (pathology)</term><term>Drug Resistance, Neoplasm (MeSH)</term><term>Enzyme-Linked Immunosorbent Assay (MeSH)</term><term>Glutaredoxins (MeSH)</term><term>Humans (MeSH)</term><term>Immunoblotting (MeSH)</term><term>Middle Aged (MeSH)</term><term>Oxidation-Reduction (MeSH)</term><term>Oxidoreductases (MeSH)</term><term>Pancreatic Neoplasms (metabolism)</term><term>Pancreatic Neoplasms (pathology)</term><term>Prognosis (MeSH)</term><term>Protein Biosynthesis (MeSH)</term><term>Thioredoxins (biosynthesis)</term><term>Thioredoxins (blood)</term><term>Tumor Cells, Cultured (drug effects)</term><term>Tumor Cells, Cultured (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Antinéoplasiques (pharmacologie)</term><term>Biosynthèse des protéines (MeSH)</term><term>Carcinome canalaire du sein (anatomopathologie)</term><term>Carcinome canalaire du sein (métabolisme)</term><term>Cellules cancéreuses en culture (effets des médicaments et des substances chimiques)</term><term>Cellules cancéreuses en culture (métabolisme)</term><term>Cisplatine (pharmacologie)</term><term>Cystadénocarcinome (anatomopathologie)</term><term>Cystadénocarcinome (métabolisme)</term><term>Glutarédoxines (MeSH)</term><term>Humains (MeSH)</term><term>Immunotransfert (MeSH)</term><term>Marqueurs biologiques tumoraux (biosynthèse)</term><term>Marqueurs biologiques tumoraux (sang)</term><term>Oxidoreductases (MeSH)</term><term>Oxydoréduction (MeSH)</term><term>Pronostic (MeSH)</term><term>Résistance aux médicaments antinéoplasiques (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Test ELISA (MeSH)</term><term>Thiorédoxines (biosynthèse)</term><term>Thiorédoxines (sang)</term><term>Tumeurs du pancréas (anatomopathologie)</term><term>Tumeurs du pancréas (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Biomarkers, Tumor</term><term>Thioredoxins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers, Tumor</term><term>Thioredoxins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents</term><term>Cisplatin</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome canalaire du sein</term><term>Cystadénocarcinome</term><term>Tumeurs du pancréas</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term><term>Thiorédoxines</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Tumor Cells, Cultured</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Cellules cancéreuses en culture</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Carcinoma, Ductal, Breast</term><term>Cystadenocarcinoma</term><term>Pancreatic Neoplasms</term><term>Tumor Cells, Cultured</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Carcinome canalaire du sein</term><term>Cellules cancéreuses en culture</term><term>Cystadénocarcinome</term><term>Tumeurs du pancréas</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Ductal, Breast</term><term>Cystadenocarcinoma</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques</term><term>Cisplatine</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term><term>Thiorédoxines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Drug Resistance, Neoplasm</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Glutaredoxins</term><term>Humans</term><term>Immunoblotting</term><term>Middle Aged</term><term>Oxidation-Reduction</term><term>Oxidoreductases</term><term>Prognosis</term><term>Protein Biosynthesis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Biosynthèse des protéines</term><term>Glutarédoxines</term><term>Humains</term><term>Immunotransfert</term><term>Oxidoreductases</term><term>Oxydoréduction</term><term>Pronostic</term><term>Résistance aux médicaments antinéoplasiques</term><term>Sujet âgé</term><term>Test ELISA</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pancreatic cancer (pancreatic ductal carcinoma) is one of the most malignant solid tumors with poor prognosis. There is accumulating evidence that cellular reduction/oxidation (redox) status is deeply involved in the growth promotion and drug resistance of cancer cells. We therefore investigated the expression of redox-regulating proteins, such as thioredoxin (TRX) and glutaredoxin (GRX) in surgically resected pancreatic tissues and cis-diamminedichloroplatinum (CDDP)-resistant cells. Plasma levels of TRX were also measured in subjects with pancreatic diseases. Pancreatic ductal carcinoma tissues were immunohistochemically more positive for TRX (24/32 cases) and GRX (29/32 cases) than pancreatic cystadenocarcinoma or normal pancreas tissues. Plasma levels of TRX (mean +/- SD) measured by ELISA were significantly higher in patients with pancreatic ductal carcinoma (54.8 +/- 37.6 ng/ml, n = 60) than in healthy controls (24.4 +/- 12.9 ng/ml, n = 81). CDDP-resistant subclones of HeLa cells, HeLa-CP5 cells, had higher expression of TRX (1.5 fold) and GRX (1.6 fold) compared with parental HeLa cells by immunoblotting. These results indicate the possible association of TRX and GRX with malignant potential of pancreatic ductal carcinoma.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10757123</PMID><DateCompleted><Year>2000</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0361-090X</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2000</Year></PubDate></JournalIssue><Title>Cancer detection and prevention</Title><ISOAbbreviation>Cancer Detect Prev</ISOAbbreviation></Journal><ArticleTitle>Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer.</ArticleTitle><Pagination><MedlinePgn>53-60</MedlinePgn></Pagination><Abstract><AbstractText>Pancreatic cancer (pancreatic ductal carcinoma) is one of the most malignant solid tumors with poor prognosis. There is accumulating evidence that cellular reduction/oxidation (redox) status is deeply involved in the growth promotion and drug resistance of cancer cells. We therefore investigated the expression of redox-regulating proteins, such as thioredoxin (TRX) and glutaredoxin (GRX) in surgically resected pancreatic tissues and cis-diamminedichloroplatinum (CDDP)-resistant cells. Plasma levels of TRX were also measured in subjects with pancreatic diseases. Pancreatic ductal carcinoma tissues were immunohistochemically more positive for TRX (24/32 cases) and GRX (29/32 cases) than pancreatic cystadenocarcinoma or normal pancreas tissues. Plasma levels of TRX (mean +/- SD) measured by ELISA were significantly higher in patients with pancreatic ductal carcinoma (54.8 +/- 37.6 ng/ml, n = 60) than in healthy controls (24.4 +/- 12.9 ng/ml, n = 81). CDDP-resistant subclones of HeLa cells, HeLa-CP5 cells, had higher expression of TRX (1.5 fold) and GRX (1.6 fold) compared with parental HeLa cells by immunoblotting. These results indicate the possible association of TRX and GRX with malignant potential of pancreatic ductal carcinoma.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biological Responses, Institute for Virus Research, Kyoto University, Sakyo, Japan. hnakamur@virus.kyoto-u.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Nishinaka</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sasada</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ohshio</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Imamura</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Takabayashi</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Yamaoka</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yodoi</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cancer Detect Prev</MedlineTA><NlmUniqueID>7704778</NlmUniqueID><ISSNLinking>0361-090X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C516005">GLRX protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054477">Glutaredoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>52500-60-4</RegistryNumber><NameOfSubstance UI="D013879">Thioredoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.-</RegistryNumber><NameOfSubstance UI="D010088">Oxidoreductases</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q20Q21Q62J</RegistryNumber><NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003536" MajorTopicYN="N">Cystadenocarcinoma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054477" MajorTopicYN="N">Glutaredoxins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010088" MajorTopicYN="Y">Oxidoreductases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014176" MajorTopicYN="Y">Protein Biosynthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013879" MajorTopicYN="N">Thioredoxins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10757123</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Japon</li></country><region><li>Région du Kansai</li></region><settlement><li>Kyoto</li></settlement><orgName><li>Université de Kyoto</li></orgName></list><tree><noCountry><name sortKey="Bai, J" sort="Bai, J" uniqKey="Bai J" first="J" last="Bai">J. Bai</name><name sortKey="Imamura, M" sort="Imamura, M" uniqKey="Imamura M" first="M" last="Imamura">M. Imamura</name><name sortKey="Nishinaka, Y" sort="Nishinaka, Y" uniqKey="Nishinaka Y" first="Y" last="Nishinaka">Y. Nishinaka</name><name sortKey="Ohshio, G" sort="Ohshio, G" uniqKey="Ohshio G" first="G" last="Ohshio">G. Ohshio</name><name sortKey="Sasada, T" sort="Sasada, T" uniqKey="Sasada T" first="T" last="Sasada">T. Sasada</name><name sortKey="Takabayashi, A" sort="Takabayashi, A" uniqKey="Takabayashi A" first="A" last="Takabayashi">A. Takabayashi</name><name sortKey="Ueda, S" sort="Ueda, S" uniqKey="Ueda S" first="S" last="Ueda">S. Ueda</name><name sortKey="Yamaoka, Y" sort="Yamaoka, Y" uniqKey="Yamaoka Y" first="Y" last="Yamaoka">Y. Yamaoka</name><name sortKey="Yodoi, J" sort="Yodoi, J" uniqKey="Yodoi J" first="J" last="Yodoi">J. Yodoi</name></noCountry><country name="Japon"><region name="Région du Kansai"><name sortKey="Nakamura, H" sort="Nakamura, H" uniqKey="Nakamura H" first="H" last="Nakamura">H. Nakamura</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/GlutaredoxinV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001071 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001071 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= GlutaredoxinV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:10757123
|texte= Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:10757123" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GlutaredoxinV1
| This area was generated with Dilib version V0.6.37. |  |